ABOUT: Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing various therapies for the treatment of various eye disorders. The company’s pipeline includes small-molecule product candidates for front and back of the eye indications. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate to reduce pupil size is in late stage clinical development for 3 indications: Reversal of Mydriasis, Presbyopia, and Night Vision Disturbances. Our second product candidate, APX3330, is a twice-a-day oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal diseases, such as diabetic retinopathy and diabetic macular edema. The company has 3 more data readouts across Phase 3 and Phase 2 trials over the next 12 months, with one recent positive Phase 3 data readout for Nyxol.
THIS INTERVIEW HAS EXPIRED